IBRX trades 29.2% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IBRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, ImmunityBio, Inc. (IBRX) has a Wall Street consensus price target of $12.00, based on estimates from 5 covering analysts. With the stock currently trading at $9.29, this represents a potential upside of +29.2%. The company has a market capitalization of $9.73B.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IBRX trades at a trailing P/E of -24.4x. Analysts expect EPS to grow -1.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NKTRNektar Therapeutics | $2.0B | $60.97 | $152.50 | +150.1% | Buy | — | 33 |
 FATEFate Therapeutics, Inc. | $301M | $2.58 | $5.63 | +118.2% | Buy | — | 31 |
 CRISCuris, Inc. | $2M | $0.98 | — | — | Buy | — | 18 |
 ADCTADC Therapeutics S.A. | $156M | $1.23 | $3.50 | +184.6% | Hold | — | 12 |
 IMVTImmunovant, Inc. | $7.7B | $37.29 | $40.00 | +7.3% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $3.4B | $26.87 | $40.00 | +48.9% | Buy | — | 18 |
 NKGNNKGen Biotech, Inc. Common Stock | $615681 | $0.01 | — | — | — | — | — |
 AGENAgenus Inc. | $362M | $8.70 | $25.00 | +187.4% | Buy | 11.2x | 11 |
 CLDXCelldex Therapeutics, Inc. | $2.2B | $33.51 | $63.88 | +90.6% | Buy | — | 19 |
 HALOHalozyme Therapeutics, Inc. | $13.7B | $115.13 | $103.00 | -10.5% | Buy | 13.7x | 27 |
Quick answers to the most common questions about buying IBRX stock.
The consensus Wall Street price target for IBRX is $12, representing 29.2% upside from the current price of $9.29. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IBRX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 29.2% upside from current levels.
IBRX's current price is $9.29 with a consensus target of $12 (29.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for IBRX, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
IBRX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IBRX stock forecast based on 5 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IBRX, with a "Buy" consensus rating and $12 price target (29.2% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IBRX analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.